Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

Standard Dose
2MG;8MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview ROSIGLITAZONE MALEATE AND GLIMEPIRIDE is listed in Drugs@FDA under application 078709 (ANDA).

Marketing status: Discontinued Active ingredient GLIMEPIRIDE; ROSIGLITAZONE MALEATE Form and strength TABLET;ORAL - 2MG;8MG Sponsor TEVA PHARMS USA Submission history Latest submission status date: 2016-04-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview ROSIGLITAZONE MALEATE AND GLIMEPIRIDE is listed in Drugs@FDA under application 078709 (ANDA). Marketing status: Discontinued Active ingredient GLIMEPIRIDE; ROSIGLITAZONE MALEATE Form and strength TABLET;ORAL - 2MG;8MG Sponsor TEVA PHARMS USA Submission history Latest submission status date: 2016-04-01 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.